Fiche centre
Parris and Associates Rheumatology
Lawrenceville — United States
Essais liés6clinical trials
VilleLawrencevillelocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT05126277
Essais cliniques associés
6| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| VAY736 1ml PFS | Lupus | Phase 2 | NCT06293365 | Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | ACTIVE_NOT_RECRUITING |
| ianalumab s.c. q4w | Lupus | Phase 3 | NCT05126277 | SIRIUS-LN — Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | ACTIVE_NOT_RECRUITING |
| Implant Procedure | SEP | Phase 3 | NCT04539964 | RESET-RA — Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis | ACTIVE_NOT_RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT05639114 | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) | ACTIVE_NOT_RECRUITING |
| LUPKYNIS | Lupus | Phase 4 | NCT07611214 | PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis | RECRUITING |
| Ianalumab | Lupus | Phase 3 | NCT06133972 | SIRIUS-SLE LTE — Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | RECRUITING |